Home Tags SH Institut fur Stoffwechselforschung GmbH
SH Institut fur Stoffwechselforschung GmbH Related Content
When it comes to trustworthy artificial intelligence (AI) in healthcare, Prof Dr Freimut Schliess from Profil GmbH, argues that now is the time to deliver.
Here, the tangible impact on diabetes patients and their care is thoroughly explored via integrated personalised diabetes management (iPDM).
Prof Dr Freimut Schliess, Director, Science & Innovation at Profil GmbH, sheds light on how Clinical Contract Research Organisations are building the digital bridge connecting clinical research and clinical care.
Taking advantage of data and trustworthy collaboration is the way to go when it comes to a life- and disease course approach to health protection and chronic care, argues Prof Dr Freimut Schliess, Director of Science & Innovation at Profil GmbH.
Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH shares his views on data-based solutions for diabetes.